18 January 2025 in Epilepsy and paroxysmal conditions
Currently, the problem of effective therapy for drug-resistant epilepsy remains vastly relevant. The severity of drug-resistant epilepsy, remarkable negative social sequelae and sudden death in epilepsy pose a heavy burden on healthcare system. Although many innovative antiepileptic drugs have been developed in recent decades, surgical approach remains the only effective way to treat drug-resistant epilepsy which is coupled to significant health risks and does not guarantee freedom from seizures. The stumbling block in managing this pathology is the lack of knowledge on pathogenetic mechanisms, leaving a significant proportion of patients without quality medical care. There are different viewpoints on developing drug resistance in epilepsy, which are characterized by multilayered and overlapping molecular disease bases. The review presents the analysis of the existing hypotheses regarding the mechanisms underlying drug resistance development in epilepsy.
2 May 2025 in Epilepsy and paroxysmal conditions
To date, despite the complexity and risks of not removing seizures hippocampal resection is the only effective solution to overcome drug resistance in epilepsy. Recently, a significant amount of data has been accumulated on the mechanisms of drug resistance development, which allows to develop innovative strategies to overcome it. New antiepileptic drugs have been emerging, directly aimed at acting on disease etiological substrate (many of them are at the stage of clinical trials). Targeted therapy have been extensively introduced, and coupled with precision medicine methods can potentially aid in finding a personalized approach to each individual patient. Migraine models also achieve a qualitatively new level, providing researchers an opportunity to develop highly effective systems for identifying previously unknown disease components, as well as assessing an effect of new drugs. The aim of this review was to highlight current approaches to the treatment of epilepsy and overcoming drug resistance.
25 January 2026 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Traumatic brain injury is one of the leading causes of disability worldwide. One of the main problems at the moment is the lack of molecular biomarkers. The previously discussed protein biomarkers of brain damage in brain injury have now been studied in more detail, but are limited by low blood concentrations and inability to penetrate the blood-brain barrier (BBB), and most are not specific to the CNS. In particular, microRNAs, short (approx. 22 nucleotides) non-coding single-stranded RNA molecules that regulate information RNA (mRNA), are well suited to the role of a biomarker of mild traumatic brain injury, as they have high sensitivity for as they have high sensitivity with respect to pathology and can be detected early in the disease. In addition, methods for their detection are minimally invasive and available in routine use. Methods quantification of microRNA expression not only allow us to distinguish trauma patients from non-traumatised controls, but also show the same promise in identifying markers of severity MicroRNAs are more valuable than the traditional protein biomarkers because they are in sufficient concentration, relatively stable in the blood and have a pronounced ability to penetrate the GEB. A large number of studies suggest that changes in microRNA expression may reflect pathological conditions. They are involved in the regulation of such processes specific to traumatic brain injury as increased oxidative stress, mycotic stress, and mycotic stress. oxidative stress, mitochondrial dysfunction, neuroinflammation, axonal degeneration. axons, inhibition of myelination and axon growth, increased apoptosis of neurons and oligodendrocytes. oligodendrocytes, and impaired autophagy and lysosomal pathways. Thus, microRNAs can be said to act as potential, convenient and accessible biomarkers of brain damage in traumatic brain injury.